CAR-T therapy is the big thing right now, with this week's approval of Gilead Yescarta and the recent approval of Novartis' Kymriah. Source: BioSpace

Universal Cells will get $9 million upfront and is eligible to regulatory milestones payments of up to $115 million, as well as royalties. Source: BioSpace

DURECT's Posimir (SABER - Bupivacaine) for post-surgical pain failed its Phase III clinical trial. Source: BioSpace

EnteroMedics recently filed with the SEC that it had raised $61M in a new equity financing round. There were 13 anonymous investors. Source: BioSpace

Shares of Arcturus are up nearly 15 percent in Thursday morning trading after the company inked a collaboration agreement with Janssen Pharma to develop a hepatitis B drug program. Source:…

WalletHub recently examined the quarterly filings of hedge funds to determine which stocks they’re buying the most. Source: BioSpace

Shortly after Rhythm made its public debut on the Nasdaq Exchange, Pfizer has snapped up a small percentage of the company focused on treating rare genetic disorders that lead to…

Vivek Ramaswamy's parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace

About 250 Pfizer employees will remain in the Memphis area after the pharma giant secured a partial tax freeze for 14 years from local governments that will save the company…

An advisory panel with the FDA gave a near unanimous support to Novo Nordisk's diabetes drug semaglutide, a long-acting GLP-1 analogue. Source: BioSpace